Edwards Lifesciences Corp - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Edwards Lifesciences Corp Company

Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.

Edwards Lifesciences Corp Info



Ticker SymbolEW

Company nameEdwards Lifesciences Corp

IPO dateMar 27, 2000

CEOMr. Bernard J. Zovighian

Number of employees15800

Security typeOrdinary Share

Fiscal year-endMar 27

AddressOne Edwards Way

CityIRVINE

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code92614

Phone19492502500

Websitehttps://www.edwards.com

Ticker SymbolEW

IPO dateMar 27, 2000

CEOMr. Bernard J. Zovighian

Company Executives of Edwards Lifesciences Corp



Name

Name/Position

Position

Shareholding

Change

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

-17.30%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.91K

+19.18%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

Dr. David T. Feinberg, M.D.

Independent Director

5.84K

+152.86%

Mr. Nicholas J. (Nick) Valeriani

Independent Chairman of the Board

--

Mr. Kieran T. Gallahue

Independent Director

--

Mr. Donald E. Bobo, Jr.

Corporate Vice President - Strategy and Corporate Development

--

Name

Name/Position

Position

Shareholding

Change

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

-17.30%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.91K

+19.18%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

By BusinessUSD

Name

Revenue

Proportion

Transcatheter Aortic Valve Replacement

1.13B

73.81%

Surgical Heart Valve Therapy

266.80M

17.41%

Transcatheter Mitral and Tricuspid Therapies

134.50M

8.78%

By RegionUSD

Name

Revenue

Proportion

United States

889.70M

58.07%

Europe

378.20M

24.68%

Rest of the world

169.00M

11.03%

Japan

95.30M

6.22%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Transcatheter Aortic Valve Replacement

1.13B

73.81%

Surgical Heart Valve Therapy

266.80M

17.41%

Transcatheter Mitral and Tricuspid Therapies

134.50M

8.78%

Shareholding Stats

Updated: Sat, Aug 16

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

11.88%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Investment Management (US)

4.37%

JP Morgan Asset Management

3.42%

Wellington Management Company, LLP

3.38%

Other

71.70%

Shareholders

Proportion

The Vanguard Group, Inc.

11.88%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Investment Management (US)

4.37%

JP Morgan Asset Management

3.42%

Wellington Management Company, LLP

3.38%

Other

71.70%

Shareholder Types

Shareholders

Proportion

Investment Advisor

43.44%

Investment Advisor/Hedge Fund

29.71%

Hedge Fund

6.65%

Research Firm

2.23%

Pension Fund

2.17%

Bank and Trust

1.92%

Sovereign Wealth Fund

1.35%

Individual Investor

0.92%

Endowment Fund

0.82%

Other

10.79%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

2562

521.87M

88.89%

-32.35M

2025Q2

2595

528.14M

89.95%

-20.66M

2025Q1

2628

535.29M

91.24%

-19.91M

2024Q4

2597

531.64M

90.42%

-4.10M

2024Q3

2568

511.38M

84.93%

-20.94M

2024Q2

2559

522.19M

86.68%

-12.58M

2024Q1

2572

518.82M

86.18%

-12.08M

2023Q4

2573

509.93M

84.08%

-27.42M

2023Q3

2530

522.96M

86.03%

-18.75M

2023Q2

2517

523.54M

86.35%

-20.02M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

69.74M

11.88%

+793.20K

+1.15%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

30.89M

5.26%

-1.39M

-4.31%

Jun 30, 2025

State Street Investment Management (US)

25.63M

4.37%

-149.08K

-0.58%

Jun 30, 2025

JP Morgan Asset Management

20.09M

3.42%

+3.72M

+22.71%

Jun 30, 2025

Wellington Management Company, LLP

19.83M

3.38%

-9.31M

-31.95%

Jun 30, 2025

Jennison Associates LLC

11.67M

1.99%

+1.58M

+15.71%

Jun 30, 2025

Citadel Advisors LLC

12.73M

2.17%

-650.39K

-4.86%

Jun 30, 2025

Geode Capital Management, L.L.C.

12.72M

2.17%

+45.55K

+0.36%

Jun 30, 2025

Walter Scott & Partners Ltd.

8.91M

1.52%

-150.07K

-1.66%

Jun 30, 2025

Union Investment Privatfonds GmbH

8.59M

1.46%

+4.67M

+119.31%

Jun 30, 2025

Related ETFs



Updated: Mon, Oct 6

Name

Proportion

iShares U.S. Medical Devices ETF

4.79%

Future Fund Long/Short ETF

3.68%

Hennessy Sustainable ETF

3.27%

Global X Aging Population ETF

3.15%

iShares Health Innovation Active ETF

3.12%

First Trust Indxx Medical Devices ETF

2.17%

Tema Heart & Health ETF

2.16%

SPDR S&P Health Care Equipment ETF

1.95%

PGIM Jennison Better Future ETF

1.93%

Invesco S&P 500 Equal Weight Health Care ETF

1.77%

iShares U.S. Medical Devices ETF

Proportion4.79%

Future Fund Long/Short ETF

Proportion3.68%

Hennessy Sustainable ETF

Proportion3.27%

Global X Aging Population ETF

Proportion3.15%

iShares Health Innovation Active ETF

Proportion3.12%

First Trust Indxx Medical Devices ETF

Proportion2.17%

Tema Heart & Health ETF

Proportion2.16%

SPDR S&P Health Care Equipment ETF

Proportion1.95%

PGIM Jennison Better Future ETF

Proportion1.93%

Invesco S&P 500 Equal Weight Health Care ETF

Proportion1.77%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

May 07, 2020

Split

1→3

Date

Type

Ratio

May 07, 2020

Split

1→3